
Precision Medicine in Oncology
Latest Content
Latest Videos

More News

An oncolytic virus called CF33 developed at City of Hope shows potential for colon cancer treatment and tumor regrowth immunity in mouse models.

Penn Medicine researchers use mice experiments to find a potential solution to the challenge of delivering CAR T cell treatments to solid tumors in glioblastoma.

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.

In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this care.

A first-of-its-kind partnership between OneOncology and Genentech aims to bring more personalized cancer care to community oncology centers nationwide.

Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.

A precision oncology tumor board at City of Hope identified colorectal cancer patients with possible hereditary predisposition who were not referred for cancer genetics evaluation previously.

In a pair of sessions at the Quality Cancer Care Alliance Virtual Fall Leadership Summit, speakers discussed the promise of precision medicine for not only informing individuals’ cancer treatment decisions but also identifying individuals at high risk before disease develops.

The liquid serum assay was cleared for use as a companion diagnostic for olaparib to identify patients with BRCA1/2- and/or ATM-mutated metastatic castration-resistant prostate cancer.

Understanding these genetic variants discovered through sequencing efforts is key to further progress in clinical genetics.

The Quality Cancer Care Alliance is focusing on 2 major topics: value-based care and innovation, and precision oncology is the intersection of those 2 issues, said Sibel Blau, MD.

Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.

The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.

The study describes how RNA sequencing and DNA sequencing for selected genes were performed simultaneously to evaluate gene expression and alterations in order to predict tumor origin.

The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.

A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.

The researchers, from a medical genetics firm, said the findings illustrate the usefulness of germline analysis for the right patient.

Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care

Next-generation sequencing (NGS) of cell-free DNA (cfDNA) may improve diagnostic testing in advanced lung cancer.

Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.

The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.

Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.

A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.

If approved, FoundationOne's CDx would be used to identify patients with non–small cell lung cancer (NSCLC) who are eligible for mobocertinib or brigatinib.

The research spotlights the diverse landscape of pediatric cancer types harboring 2 types of genomic alterations.








